Omega-3 fatty acids may improve vision in dry AMD

Source/Disclosures

Source:

Prokopiou E, et al. A prospective, randomized, multicenter, double-blind, placebo-controlled study evaluating the potential effects of omega-3 fatty acid supplementation on dry age-related macular degeneration and Stargardt disease. Presented at the Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.

Disclosures:
Prokopiou does not report any relevant financial information.


We have not been able to process your request. Please try again later. If you continue to have this problem, please contact [email protected]

DENVER — Omega-3 fatty acid supplements may improve vision in patients with age-related macular degeneration and Stargardt disease, a study has found.

At the meeting of the Association for Research in Vision and Ophthalmology, Ekatherine Prokopioudoctorate, said previous preclinical work has shown that omega-3s may have protective potential, including for retinal degeneration.

Ekatherine Prokopiou

“We used an omega-3 formulation rich in EPA,” Prokopiou told Healio/OSN. “We believe this is one of the most important omega-3 fatty acids.”

The effects of omega-3 fatty acids were studied in a randomized controlled trial in 21 subjects who received either a placebo or active omega-3s for 24 weeks. The primary endpoint of the study was the number of letters gained in best corrected visual acuity from baseline at 12 weeks and 24 weeks. Subjects also completed a perceived vision questionnaire at 12 weeks and 24 weeks.

In the active group, mean BCVA increased from 40.93 letters at screening to 46.93 letters at week 24 (P = 0.003) compared to no significant increase in the placebo group. When the two groups were compared, a significant difference existed between the active and placebo groups (P = .002). Similar results were found at week 12.

Although the mean questionnaire score was similar between the two groups at week 12, the score was higher in the active group at 9.38 compared to the placebo group at 7.28 at week 24.

Prokopiou said EPA-rich omega-3 fatty acid supplements can improve objective and subjective vision in patients with AMD.

“It’s something that’s pretty simple, well tolerated in patients so they don’t have any adverse effects, and it’s something that you see the effects of in both eyes,” Prokopiou said. “We think it could be something that could be used as an official supplement for these patients to improve their vision and prevent disease progression.”

Comments are closed.